PTX200 is undergoing an AML trial at the moment. A dose increase was announced recently. We should have a readout towards the end of the year.
Although the TCL market is small, it has no real SOC. This means the FDA will look favourably towards fast tracking drug approval. Once the drug has approval, they can then expand it use. This is exactly what some CarT and the Amgen Kras drugs have done. Its a smart move.
PTX Price at posting:
18.3¢ Sentiment: Buy Disclosure: Held
